- Following a review of safety data by an independent committee, a Phase 3 clinical trial evaluating AstraZeneca's (NASDAQ:AZN) COVID-19 vaccine candidate, AZD1222, has resumed in Japan following earlier restarts in the U.K., Brazil, South Africa and India.
- The U.S. study has yet to resume.
- https://seekingalpha.com/news/3619310-study-of-astrazeneca-covidminus-19-vaccine-resumes-in-japan
Friday, October 2, 2020
Study of AstraZeneca COVID-19 vaccine resumes in Japan
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.